|Bowdoin College, BA|
|University of California, Los Angeles (UCLA), MBA|
Larry is a Special Limited Partner and currently serves as Chairman of Lux Ventures’ Advisory Board of industry experts advising the Investment Team.
Larry was a co-founder and executive chairman of Nanosys, Inc. Prior to Nanosys, he was a managing general partner of CW Group, a life sciences venture capital fund. Larry was also a general partner of Avalon Ventures, a seed stage venture capital firm.
Larry has been the founder and initial chief executive officer of Metra Biosystems, Inc., Neurocrine Biosciences, Inc. (NASDAQ: NBIX - neuroimmunology), Pharmacopeia, Inc. (NASDAQ: PCOP - combinatorial chemistry), Argonaut Technologies, Inc (NASDAQ: AGNT - combinatorial chemistry), and Caliper Technologies Corp (NASDAQ: CALP - lab-on-a-chip).
Mr. Bock was also a co-founder of ARIAD Pharmaceuticals, Inc (NASDAQ: ARIA - intra cellular signal transduction), Athena Neurosciences (NASDAQ: ATHN, acquired by Elan Pharmaceuticals for $700M - molecular neurobiology) Inc., GenPharm International (acquired by MedaRx - transgenic animals), Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX - rational drug design), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX - molecular oncology) and Illumina, Inc. (NASDAQ: ILMN - array-based optical sensors).